- Home
- ZCMD vs INKT Comparison
ZCMD vs INKT Comparison
Compare ZCMD & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZCMD
- INKT
- Stock Information
- Founded
- ZCMD 2012
- INKT 2017
- Country
- ZCMD China
- INKT United States
- Employees
- ZCMD N/A
- INKT N/A
- Industry
- ZCMD Other Consumer Services
- INKT Medicinal Chemicals and Botanical Products
- Sector
- ZCMD Real Estate
- INKT Health Care
- Exchange
- ZCMD Nasdaq
- INKT Nasdaq
- Market Cap
- ZCMD 29.0M
- INKT 28.8M
- IPO Year
- ZCMD 2020
- INKT 2021
- Fundamental
- Price
- ZCMD $1.14
- INKT $40.61
- Analyst Decision
- ZCMD
- INKT Buy
- Analyst Count
- ZCMD 0
- INKT 3
- Target Price
- ZCMD N/A
- INKT $37.50
- AVG Volume (30 Days)
- ZCMD 506.1K
- INKT 2.6M
- Earning Date
- ZCMD 01-01-0001
- INKT 08-12-2025
- Dividend Yield
- ZCMD N/A
- INKT N/A
- EPS Growth
- ZCMD N/A
- INKT N/A
- EPS
- ZCMD N/A
- INKT N/A
- Revenue
- ZCMD $15,864,773.00
- INKT N/A
- Revenue This Year
- ZCMD N/A
- INKT N/A
- Revenue Next Year
- ZCMD N/A
- INKT N/A
- P/E Ratio
- ZCMD N/A
- INKT N/A
- Revenue Growth
- ZCMD N/A
- INKT N/A
- 52 Week Low
- ZCMD $0.95
- INKT $4.56
- 52 Week High
- ZCMD $2.97
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- ZCMD 48.00
- INKT 68.63
- Support Level
- ZCMD $1.13
- INKT $6.80
- Resistance Level
- ZCMD $1.24
- INKT $76.00
- Average True Range (ATR)
- ZCMD 0.11
- INKT 5.71
- MACD
- ZCMD -0.01
- INKT 4.21
- Stochastic Oscillator
- ZCMD 21.84
- INKT 48.86
About ZCMD Zhongchao Inc.
ZHONGCHAO Inc is an offshore holding company incorporated in the Cayman Islands. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provide the healthcare information, education, and training services to the healthcare professionals under their MDMOOC brand. It also provide focused patient management services, through Zhongxun IT system and WeChat mini program and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.